DXCMBy Calypso Research8 min read

Dexcom (DXCM) Q4 2025 Earnings Analysis

Glucose Gains: Dexcom Sweetens $1.3B Revenue Surge

Key Takeaways

Dexcom (DXCM) reported Q4 2025 earnings with revenue of $1.3B, representing a +13.1% year-over-year change. The stock moved +7.6% on earnings day.

The bull case: Bulls see Dexcom leveraging expanding T2 coverage, 15‑day G7, and a rapidly scaling international and software platform to sustain mid‑teens volume growth with rising margins and a much larger global CGM footprint over time.

The bear case: Bears worry that delayed CMS timing, pricing and competitive‑bid pressure, intensifying global competition, and mix shift into lower‑priced segments will compress revenue per patient and cap margin expansion despite heavy investment in capacity and innovation.

Financial Highlights

  • Revenue: $1.3B (+13.1% YoY)
  • Gross Profit: $793M (62.9% margin, +4.0% YoY)
  • Operating Income: $323M (25.6% margin, +8.7% YoY)
  • Net Income: $267M
  • TTM Revenue: $4.7B

Stock Performance

  • Earnings Day Move: +7.6%
  • Year-to-Date: +10.1%
  • 1-Year Return: -19.3%
  • vs. S&P 500 (since earnings): +10.7%
  • vs. Nasdaq (since earnings): +13.4%

View live DXCM data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Dexcom's Q4 2025 earnings call:

Timing, scale, and economics of Type 2 Non‑Insulin (T2 NIT) coverage (CMS + commercial)

Sentiment: Positive

"we have started, you know, towards last year, seeing coverage unlocked commercially for type two non insulin users, and we are on the verge of of expansion into the broader group of type two that are covered by Medicare. And so when that expansion happens, it is almost 12,000,000 people would then suddenly get access to CGM." — Jacob Steven Leach
"This guidance assumes continued strong category growth and incremental growth contribution from Stelo, and new product advancements across our platform. It also assumes that the coverage landscape remains predominantly the same as it stands today, but we will continue to push for additional CGM access globally." — Jereme M. Sylvain

G7 15‑Day Sensor: Margin Tailwind vs. Adoption / Reliability Risk

Sentiment: Positive

"as we think about the fifteen day product, you know, clearly in the US, it is launched today, and and and we would expect that to to certainly start to contribute to margins over the course of this year. The reality is it starts to contribute to margins even more in future years because this is a year about getting folks interested, making sure they understand the benefits, really converting a base over time." — Jereme M. Sylvain
"the fifteen day product got all of that from day one, so as we launched this new version of G7, seeing great feedback about both the longevity of the sensor, the reliability, but also the accuracy. This is the most accurate sensor we have ever produced. And users are noticing it." — Jacob Steven Leach

2026 Revenue Growth Bridge and New‑Patient vs. Base Dynamics

Sentiment: Positive

"we exit the year... talking about patient base growing at about 20%. Almost 20%. And so that is your starting point for what you would expect in terms of starting point for volumes as you move into the year... our expectation... is we have a couple points of price... and the remainder in the delta what I would say is any anticipations around unit volumes would be around mix." — Jereme M. Sylvain
"We do not necessarily need a record new patients to hit the the low end of our guidance. And you would wanna hit a record new patient to certainly hit the top end of the range and and beyond." — Jereme M. Sylvain

Utilization, Retention, and the Impact of Expanding into Basal and T2 NIT Populations

Sentiment: Positive

"the highest utilization we see in those those AID users type one on automated and some delivery systems, you know, they are they are well north of 90% utilization... type two base... has about an 85 to 80% utilization rate... In the registry... for CGM, that are type two non insulin users... we are seeing high utilization rates in that group very similar to those basal when you are in a reimbursed environment." — Jacob Steven Leach
"Think the best way to take it, Danielle, is at least back to the models is to think about it as the utilization, the trends have remained the same. In fact, there is work we are doing to make them better. It is just really more about the mix." — Jereme M. Sylvain

OpEx Discipline vs. Step‑Up Investment (Ireland Facility, Innovation, and Growth)

Sentiment: Mixed

"the leverage in the P&L next year predominantly will flow through gross margin. And and the goal is to keep the op margin or the op expenses as a percent flat... what is running through that P&L is the launch of our Ireland manufacturing facility... there is a big investment in that in that manufacturing facility... At which point those costs will come out of OpEx and up into COGS." — Jereme M. Sylvain
"it is all a moot point across the board when you look at op margin. Because it is all geography." — Jereme M. Sylvain

Bull Case

Bulls see Dexcom leveraging expanding T2 coverage, 15‑day G7, and a rapidly scaling international and software platform to sustain mid‑teens volume growth with rising margins and a much larger global CGM footprint over time.

Bear Case

Bears worry that delayed CMS timing, pricing and competitive‑bid pressure, intensifying global competition, and mix shift into lower‑priced segments will compress revenue per patient and cap margin expansion despite heavy investment in capacity and innovation.

Looking Ahead

With revenue growing +13.1% year-over-year, the key question is whether Dexcom can sustain this growth trajectory, particularly around timing, scale, and economics of Type 2 Non‑Insulin (T2 NIT) coverage (CMS + commercial). With operating margins at 25.6%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Dexcom's revenue in Q4 2025?

Dexcom reported Q4 2025 revenue of $1.3B, representing a +13.1% year-over-year change.

Did Dexcom beat earnings expectations in Q4 2025?

The stock rose +7.6% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Bulls see Dexcom leveraging expanding T2 coverage, 15‑day G7, and a rapidly scaling international and software platform to sustain mid‑teens volume growth with rising margins and a much larger global CGM footprint over time.

What is the bull case for DXCM stock?

The bull case for DXCM centers on: Bulls see Dexcom leveraging expanding T2 coverage, 15‑day G7, and a rapidly scaling international and software platform to sustain mid‑teens volume growth with rising margins and a much larger global CGM footprint over time.

What is the bear case for DXCM stock?

The bear case for DXCM centers on: Bears worry that delayed CMS timing, pricing and competitive‑bid pressure, intensifying global competition, and mix shift into lower‑priced segments will compress revenue per patient and cap margin expansion despite heavy investment in capacity and innovation.

How has DXCM stock performed since its Q4 2025 earnings?

DXCM moved +7.6% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +10.7% since earnings. Year-to-date, the stock has returned +10.1%.

Browse all 400+ earnings reports →

Learn More

Analyze DXCM in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Dexcom and 400+ other stocks, explore the full platform.

Open DXCM on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.